{
    "nct_id": "NCT04672434",
    "official_title": "A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies",
    "inclusion_criteria": "* Male or female patients, â‰¥18 years.\n* Documented (histologically or cytologically proven), locally advanced or metastatic solid tumor malignancy (must be one of the following):\n\n  1. Squamous cell carcinoma of the head and neck\n  2. Non-small-cell lung carcinoma-adenocarcinoma histology subtype\n  3. Pancreatic ductal adenocarcinoma\n  4. Cholangiocarcinoma\n  5. Colorectal carcinoma (microsatellite stable [MSS] and microsatellite instability-high [MSI-H] phenotypes)\n  6. Gastric carcinoma (includes gastroesophageal carcinoma)\n  7. Esophageal carcinoma (includes squamous cell and adenocarcinoma)\n  8. Mesothelioma (pleural and peritoneal)\n  9. Cervical carcinoma (CC) (includes adeno, squamous and mixed adeno-squamous carcinoma histology subtypes)\n* Malignancy that is not currently amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.\n* Measurable disease according to RECIST v1.1.\n* Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.\n* Agreeing to mandatory tumor tissue biopsies (2 total).\n* ECOG PS of 0 or 1.\n* Adequate organ function as indicated by the following laboratory values.\n* Adequate contraception required as appropriate.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Central nervous system (CNS) malignancies.\n* Clinically significant cardiovascular disease or condition.\n* Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study drug(s).\n* Active uncontrolled bleeding or a known bleeding diathesis.\n* Significant ocular disease or condition.\n* Significant pulmonary disease or condition.\n* Current or recent (within 6 months) significant gastrointestinal disease or condition.\n* Active, known or suspected autoimmune disease.\n* History of organ transplantation (i.e., stem cell or solid organ transplant).\n* Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).\n* Any other serious/active/uncontrolled infection.\n* History of significant toxicities associated with previous administration of immune checkpoint inhibitors.\n* Known or suspected hypersensitivity to any of the excipients of formulated study drug.\n* Unresolved >Grade 1 toxicity associated with any prior antineoplastic therapy.\n* Inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to the first dose of study drug(s).\n* Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy).\n\nTherapeutic Exclusions\n\n* Prior therapy with Sym024 or other inhibitors of CD73, CD39 or adenosine receptors ADORA2A, ADORA2B.\n* Part II and Part III, prior anti-PD-(L)1 therapy, except for indications where it is approved.\n* Any antineoplastic agent for the primary malignancy (standard or investigational) within 4 weeks or 5 elimination half-lives.\n* Any other investigational treatments within 2 weeks prior to the first dose of study drug(s).\n* Radiotherapy, with exceptions.\n* Live vaccines against infectious diseases 4 weeks prior to the first dose of study drug(s).\n* Immunosuppressive or systemic glucocorticoids therapy (>10 mg daily prednisone or equivalent) within 2 weeks prior to the first dose of study drug(s), with exceptions.\n* Prophylactic use of hematopoietic growth factors within 1 week prior to the first dose of study drug(s).",
    "miscellaneous_criteria": ""
}